Royalty Report: Drugs, Disease, Vaccine – Collection: 274922

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Disease
  • Vaccine
  • HPV
  • HIV / AIDs
  • Cancer
  • DNA
  • Therapeutic
  • Delivery
  • Diagnostic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 274922

License Grant
The Parties agreed to amend and restate several sections of the original agreement to include but not limited to the following

Licensor hereby grants non-exclusive licenses (other than the Co-exclusive License for Therapeutic Immunization for HPV Antigens granted in this Agreement C below) in accordance with the terms stated herein.

In consideration of the obligations assumed by Licensee hereunder, Licensor hereby grants to Licensee and to any affiliates of Licensee the following licenses without the right to sublicense as set forth in this paragraph under technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the territory and in the field all products and/or compinations, subject to the following

(A1) For prophylactic immunization within the field, Licensor grants a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens
HBV Antigens
Influenza Antigens
Chlamydia Antigens
Mycobacterium Antigens
RSV Antigens
Malaria Antigens
Steptococcus pneumonia Antigens

(A2) For prophylactic immunization within the field, Licensor grants to Licensee a non-exclusive license for the following licensed antigens and no other antigens.

HIV Antigens

(B) For therapeutic immunization within the field, Licensor grants Licensee a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HBV Antigens
Chlamydia Antigens
Mycobacterium Antigens

(C) For therapeutic immunization within the field, licensor grants Licensee a co-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens

The regulatory and development milestone payments and the patent royalties for each Licensed Antigen in the non-exclusive licenses granted in (A1) and (B) shall be reduced by a certain percent.

License Property
The Products are for therapeutic immunization relating to infectious diseases that such as

HBV  – hepatitis B virus
HPV – human papillomavirus
HIV – human immunodeficiency virus

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 249711

License Grant
Licensor grants a co-exclusive license, except non-exclusive license for HIV, in accordance with the terms stated herein.

Licensor grants to the United Kingdom Licensee and to any affiliates the following licenses, with the right to grant sublicenses, under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field all Products and/or Combinations, subject to the following
– For Prophylactic Immunization within the Field, Licensor grants a Co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• INFLUENZA ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS
• RSV ANTIGENS
• Malaria ANTIGENS

– For Prophylactic Immunization within the Field, Licensor grants a non-exclusive license for the following Licensed Antigens and no other Antigens
• HIV ANTIGENS

– For Therapeutic immunization within the Field Licensor grants a co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS

License Property
The Product shall mean any and all pharmaceutical compositions for the Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, to the extent Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of such Licensed Antigens contained within Product.

The patents relate to the use of Nucleic Acid.

Field of Use
The field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans, expressly excluding the Specific Field.

Specific Field shall mean the use of Adjuvant as part of or in conjunction with a DNA Vaccine or other than in combination with a Licensed Antigen.

IPSCIO Record ID: 249713

License Grant
Licensor grants to Licensee of the United Kingdom a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain any of the following two Licensed Antigens
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.

In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens
• Any and all Antigens expressed in Lung Cancer

License Property
The Product shall mean any and all pharmaceutical compositions for Prophylactic Immunization and/or Therapeutic Immunization in the field comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, in which Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of any of such Licensed Antigens contained within Product.

The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.

Field of Use
The Field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for the purpose of inducing, augmenting, fine-tuning or enhancing in vivo, in vitro or ex vivo of an Antigen specific immune response and in all cases for Prophylactic Immunization and/or Therapeutic Immunization against Licensed Cancers in humans, excluding Specific Field.

Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.

IPSCIO Record ID: 368651

License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.

The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.

Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.

Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.

TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products.  This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.

The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.

This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).

IPSCIO Record ID: 279370

License Grant
Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license, including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in the Territory excluding Canada; and (b) Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in Canada.

The exclusivity of the foregoing license shall be subject to the retained right of Licensors and their respective Affiliates to practice the Licensor Technology for the purpose of conducting development, manufacture and commercialization of Target Products in the Territory to the extent expressly contemplated by this Agreement.

License Property
HspE7 shall mean any fusion protein containing (a) a human papilloma virus (HPV) E7 antigen, or an antigenic fragment, mutein or conjugate thereof, and (b) a bacterial stress protein, or a fragment, mutein or conjugate thereof, including, in particular and without limitation, that recombinant DNA derived fusion protein containing 638 amino acids, derived from the 65kDa heat shock protein of mycobacterium bovis var. BCG (Hsp65) coupled at the C-terminus to the E7 protein of human papilloma virus (HPV) type 16.  HspE7 includes nucleic acid sequences and vectors and host cells containing nucleic acid sequences encoding such proteins contained therein.

Licensor Technology shall mean the Licensor Know-How and the Licensor Patent Rights..
Licensor Patent Rights shall mean all Patents that Licensor  Controls as of the Execution Date or during the Term, including, without limitation, Patents that claim Licensor Inventions and/or Joint Inventions, which, in the absence of the license granted to Licensee under this Agreement, would be infringed by the making, using, selling, offer for sale or importation of Target Products in the Territory.  The Agreement lists all Licensor Patent Rights existing as of the Execution Date (Base Patents).

US Patent #6,338,952 – Stress proteins and uses therefor
US Patent #6,335,183 – Stress proteins and uses therefor

Field of Use
HspE7 targets a broad spectrum of human papillomavirus ('HPV') related diseases.

IPSCIO Record ID: 28073

License Grant
The Canadian University hereby grants to the Canadian Licensee an exclusive world-wide license, in respect of the Type I Technology and a non-exclusive world-wide license in respect of the Type II Technology, to make use of, or caused to be used, sell and/or sublicense the Technology and any know how associated therewith or which forms a basis thereof whether it is the Scientist's know how, and to manufacture, commercialize, distribute, market, import, export, offer to sell, sell, lease and/or license or sublicense Products on the terms and conditions hereinafter set forth (the License).
License Property
The Scientist of  the University has been engaged in research during the course of which he has developed certain recombinant viral antigens, murine antibody clones and an animal model.

Type I Technology shall mean the recombinant viral antigens and murine antibody clones and Type II Technology shall mean the animal model.

1. Antigens cloned, expressed and purified in the Tyrrell University laboratory as follows

·
Human Hepatitis B(HBV) Core Antigen (short)

·
Duck Hepatitis B(DHBV) Surface Antigen

·
Duck Hepatitis B(DHBV) Polymerase Protein

·
Duck Hepatitis B(DHBV) Core Protein

2. Murine antibody clones developed in the Tyrrell University laboratory as follows

·
Monoclonal Antibody 1D12 to HBV core antigen

·
Monoclonal antibodies 2C12, 2D12, 2C11, 2A12, 4A10, 1F9, 2G11 to HBV surface antigen

·
Monoclonal Antibody 3A8, 2C4 to HBV Polymerase

·
Monoclonal Antibody 1F4 to DHBV Surface Antigen

·
Monoclonal Antibodies 9A8, 8D6, 7G4, 7G5, 7G10, 9F2, 9G8, 1A9, 4A9, 1H5 to DHBV Core Antigen.

3. Animal model as follows

·
Hepatitis B Duck Model

Including any replications of progeny of the above made by the Licensee and, if that which is made by the Licensee, constitutes cells or DNA molecules. Type II Technology includes all modifications, improvements and variants thereof and any data or information in relating thereto including sequence information.

Field of Use
Licensee will be commercializing novel therapeutic approaches to treat diseases, excluding cancer, in humans created by identifiable microbial pathogens.

IPSCIO Record ID: 277105

License Grant
For outside the licensed field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell Licensee Products outside the Licensed Field.

This agreement contains both exclusive and non-exclusive grants between the parties.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.  First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.

IPSCIO Record ID: 336296

License Grant
Licensor hereby grants to United Kingdom Licensee and its Affiliates an exclusive, royalty-bearing license throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under Licensors interest in the Licensor Patents, Licensor Technology and Joint Inventions, to develop, register, use, make, have made, import, export, offer to sell, sell and have sold HPV Vaccines and/or Antigens and/or Process.  Licensee agrees that it will use Licensor Technology and Licensor Patents only as licensed under this Agreement.
License Property
HPV Vaccine shall mean a vaccine for the prevention, control or treatment of human papilloma virus infection in humans in any formulation, configuration or delivery system or a product or process for the diagnosis of HPV infection in humans.

Antigen shall mean (i) HPV antigens and/or (ii) HPV proteins and/or (iii) other physical forms based on such antigens, such as peptides and/or nucleic acid(s) (DNA, RNA) delivered in any form including recombinant vectors.

Vaccine Product shall mean an HPV Vaccine (x)covered in whole or in part by a Licensor Patent or an Licensee Patent which covers Licensee Special Technology and/or (y) which incorporates or is derived from the use of Licensor Technology and/or Licensee Special Technology.  

Licensor Patents shall mean
5,298,418 – Cell line isolated from larval midgut tissue of Trichoplusia ni
5,300,435 – Trichoplusia ni cell line which supports replication of baculoviruses
5,437,951 – Self-assembling recombinant papillomavirus capsid proteins

Licensor Technology shall mean information, know-how and materials, including, but not limited to, pharmaceutical, chemical and biological products, technical and non-technical data and information (i) owned by Licensor and/or to which Licensor has a transferable interest on the Effective Date and/or at any time during the term of this Agreement and (ii) which relate to the field of L1 based HPV Vaccines and/or which arise from the Research Program, and in each case which are necessary or useful for the development, manufacture, use or sale of an HPV Vaccine.

Field of Use
Field of use is for the treatment for the human papilloma virus (AHPV@) (HPV).

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI).
Many people with HPV don't develop any symptoms but can still infect others through sexual contact. Symptoms may include warts on the genitals or surrounding skin.
There's no cure for the virus and warts may go away on their own. Treatment focuses on removing the warts. A vaccine that prevents the HPV strains most likely to cause genital warts and cervical cancer is recommended for boys and girls.

IPSCIO Record ID: 273462

License Grant
Licensor grants a worldwide, exclusive, and sublicensable right and license to practice the Licensor Technology and all of Licensors rights in Collaboration Patent Rights to make. have made. use. import, promote, market,  or sell Licensed Products in the Licensed Field.

Licensor grants a worldwide, exclusive or non-exclusive, as the case may be, and sublicenseable  right and license to practice the Third Party Technology to make, have made, use, import, promote, market, distribute or sell Licensed Products in the Licensed Field.

For the Grant of License to Joint Collaboration Patent Rights Outside the Licensed Field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell products or processes outside the Licensed Field.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.   First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.

IPSCIO Record ID: 257492

License Grant
Pursuant to the Agreement, Licensee obtained an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed Products in the Territory.

With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.

As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.

Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.

Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.

License Property
This amendment includes Amended Definitions Relating to Cancer targets, and, Licensed Product means a bulk or finished AIDS Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the research collaboration program; and upon the exercise of an Option for a Cancer vaccine, such bulk or finished Cancer vaccine for the prevention of Cancer Indications, provided, however, that if any vaccine is also capable of being used for treatment of the same human infectious disease or Cancer indication, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement; and Treatment vaccines.

Treatment vaccines means a bulk or finished vaccine.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-1 in humans;  Hepatitis Virus (HBV) and or diseases caused by infection with HBV in humans; and Cancer vaccines for the treatment, but not prevention or prevention and treatment, of Cancer Indications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.